Navigation Links
RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
Date:12/4/2013

WESTBOROUGH, Mass., Dec. 4, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced additional results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA® compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

(Logo:  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO )

In this study, subjects received small skin incisions in their abdomen and were treated with three intradermal doses of RXI‑109 over a 2-week period.  The dose escalating portion of the study consisted of four cohorts of three healthy volunteers each.  An additional 5th cohort was also added at the highest dose, in which the treatment period was delayed by two weeks. Subjects received RXI‑109 on one side of the abdomen, and placebo on the other side. Subjects were monitored for safety and local and systemic side effects over a total study period of 84 days. Multiple dermal injections were well tolerated at all doses, and treatment with RXI‑109 resulted in dose-dependent silencing of CTGF mRNA in the treated areas. In the additional 4th cohort of this study, three doses of 10 mg dose per incision over the initial 2-week period following the incision averaged approximately 50% reduction of CTGF mRNA expression compared to placebo when measured three days after the last dose. In the 5th cohort, where the dosing period with 10 mg RXI-109 per incision was delayed by 2 weeks after the incisions were made, no additional benefit was seen on m
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that the ... its Data Monitoring Committee's (DMC),review of preliminary ... patients with newly diagnosed multiple myeloma has ... of dexamethasone (Decadron) in,combination with lenalidomide suggests ...
... HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. ... an important,pilot study with a novel synDNA(TM) ... protect against the avian (H5N1),influenza virus. The ... mice treated with the Company's synDNA(TM) vaccine,whereas ...
Cached Medicine Technology:ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2
(Date:9/1/2014)... September 01, 2014 The B-cell non-Hodgkin’s ... across six major markets (the US, France, Italy, Germany, ... to $5.41 billion by 2018. , The competitive landscape ... Italy, Germany, Spain and the UK is poised to ... management of the four largest B-cell NHL indications, which ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... As well as having completed the ... pursuing counselor certification in Louisiana. , "I ... training program as well as the Counselor training ... personally and professionally. I am not only dedicated ... to do so. As a Non Violent Crisis ...
(Date:9/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , the global market for ... and is expected to reach $38.7 million in 2014. ... by 2019, which is equivalent to 64.9% compound annual ... transport (RMT) segment is forecasted to grow at a ...
(Date:9/1/2014)... Oakdale, MN (PRWEB) September 01, 2014 In honor ... place on Aug. 22, Animal Emergency & Referral Center of Minnesota ... veterinarian visits a priority for their cats. , Many people don’t ... “it’s too much of a hassle,” but they wouldn’t decide not ... no signs of a cavity. The same goes for pets. Just ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... GAITHERSBURG, Md., Dec. 5 Panacea Pharmaceuticals, ... a fully human sequence,monoclonal antibody against HAAH ... in collaboration with the Massachusetts Institute of ... efficacy in animal,models of cancer. Having a ...
... publication Head and Neck Pathology. Published under the Humana ... North American Society for Head and Neck Pathology (NASHNP). ... December 2007, it will be available free of charge for ... Pathology will present scholarly papers, reviews and case reports that ...
... new ways of tweaking the molecular structure of antibiotics ... fight against powerful super bugs. , The work, led ... geneticist Professor Colin Smith, is published online today (Wednesday ... of the Journal of the American Chemical Society. , ...
... Clinical study compares rotational stability of two differently designed, ... of every day viewing conditions, JACKSONVILLE, Fla., Dec. ... vision may sometimes fluctuate during the day, the answer,may ... new clinical study,demonstrates. The findings, say researchers, may be ...
... Inc., a,medical device company developing endovascular devices for ... announced,the appointment of Christopher R. Barys to the ... to FlowCardia with over 16 years of,experience in ... in the,interventional endovascular products field., Most recently, ...
... Alliance, the leading,management consulting firm specializing in the ... Vice President,of the firm,s Business Development practice, will ... at the Strategic Research,Institute,s (SRI) Pharma & Biotech ... on December 10-11, 2007, at the San Diego ...
Cached Medicine News:Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 2Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 3Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 4Health News:Scientists strike blow in superbugs struggle 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 3Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 4Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 5Health News:FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: